Pieris Pharmaceuticals (NASDAQ: PIRS) is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. 

Pharmaceutical

Pieris Pharmaceuticals

Pieris Pharmaceuticals' headquarters in Boston, MA, United States

Stephen S. Yoder

Frank Vollmering

Shane Olwill

Tom Bures

James Geraghty

Michael Richman

Christopher Kiritsy

Ann Barbier

Peter Kiener

Maya R. Said

Padmanee Sharma

Vijay Kuchroo

Matthew L. Sherman

Michael Curran

Dario Vignali

Ian Adcock

Bruce Levy

E. John Werry

David Schwartz

Sally Wenzel

Peter Barnes

Gary Anderson

Oliver Eickelberg

Fan Chung

The Board Members at Pieris Pharmaceuticals play a crucial role in providing strategic direction, governance, and oversight for the company's operations and research initiatives. They leverage their diverse expertise in biotechnology, finance, and corporate governance to guide the development of Anticalin-based drugs and ensure alignment with the company’s mission to innovate in addressing validated disease pathways. Additionally, they facilitate key decisions regarding funding, partnerships, and long-term growth strategies.

Board Members

The Leadership Team at Pieris Pharmaceuticals drives the strategic direction and overall vision of the company, ensuring alignment between business objectives and scientific innovation. This diverse team, comprising experts in human resources, finance, project leadership, and development, collaborates to oversee clinical advancements, manage partnerships, and foster a culture of excellence within the organization, ultimately aiming to propel Anticalin-based therapies from discovery to market.

Leadership Team

Pieris Pharmaceuticals

Org chart

Board & advisors

Teams

Board Members

Leadership Team

Offices

Pieris Pharmaceuticals

Org chart

Board & advisors

Teams

Board Members

Leadership Team

Offices

Related companies